FDA’s Industry User Fee Package Advances to Full House Panel (1)

A key House panel on Wednesday approved a comprehensive package reauthorizing the user fees that help fund the FDA, including policy proposals to improve the accelerated approval pathway and remove barriers to generic drug competition.

The House Energy and Commerce Committee’s Subcommittee on Health voted 30-0 to advance the bill (H.R. 7667), a key step toward full passage of the agreements between the Food and Drug Administration and the drug and device industries. User fees make up nearly half of the FDA’s funding, and must be reauthorized before the current user fee agreements expire Sept. 30.

“This package ...